Advances in Cancer Immunotherapy | Keystone Symposia

March 22-26, 2020
Fairmont Chateau Whistler
Whistler, BC Canada

Visit our poster number 1001 on Monday, March 23, 2020 at Poster Session 1

Immuno-phenotyping of tumor-specific CD8 T cells using high-dimensional mass cytometry.

Cancer immunotherapy is providing an unprecedented level of long-term antitumor activity in some patients, but unfortunately the majority of patients still do not experience sustained clinical benefit. Many questions remain unanswered. The conference program will include sessions which cover topics such as new analysis techniques, methodologies, and how to integrate high throughput data to provide a more comprehensive understanding of cancer and the immune system.

Click here to learn more about this conference.

Molecular Med TRI-CON | Advancing Precision Medicine

March 1-4, 2020
Moscone South Convention Center
San Francisco, CA

Visit our poster on March 2-3 – Poster #36
Immuno-phenotyping of tumor-specific CD8 T cells using high-dimensional mass cytometry.

The Molecular Medicine Tri-Conference will showcase new technologies to advance precision medicine along with emerging
therapeutics across a spectrum of applications. Key opinion leaders will discuss the latest tools, clinical advances, and commercial applications of a broad range of new and diverse products for vast improvements in medicine and healthcare.

Click here to learn more about this conference.

Get a chance to meet Dr. Evan Newell at SNO Think Tank Meeting on “Immunotherapy in Neuro-Oncology: Promises and Challenges”

2019 SNO Annual Meeting
Innovation to Overcome Tumor Resistance
Wed., Nov. 20 (Pre-Meeting)
Thursday, Nov. 21 (Education Day)
Friday, Nov. 22 – Nov. 24 (Main Meeting)

This meeting will be held Wednesday, November 20, 2019, at the Marriott Desert Ridge Hotel in Phoenix, Arizona, immediately preceding the SNO Annual Meeting.

Dr. Evan Newell will be speaking on the topic: Profiling of tumor-specific vs bystander tumor-infiltrating T cells

Click here for more information.


Attend Dr. Newell’s talk at Samsung Global Research Symposium on T cell Biology

November 7-8, 2019
Samsung Semiconductor, Inc
3655 North First Street, San Jose, CA 95134, USA

Dr. Evan Newell will be presenting a talk on, “Profiling antigen-specific T cells to understand T cell diversity in human health and disease



Visit us at the World Vaccine and Immunotherapy Congress West Coast 2019

December 3-5, 2019
Congress Centre
San Francisco Airport Marriott Waterfront
San Francisco, CA

This conference is dedicated to the vaccine industry with a focus on integrating the technologies revolutionizing immunotherapy and its impact on vaccine development. It brings together senior attendees from the vaccine and immunotherapy industry. 

Click here for more information about the conference.

Click here to view a .pdf of our poster in more detail.


AACR's Tumor Immunology & Immunotherapy Conference

Come see us at AACR’s Tumor Immunology & Immunotherapy Conference 2019

November 17-20, 2019
Boston Marriott Copley Place
Boston, Massachusetts

This AACR Special Conference on Tumor Immunology and Immunotherapy is designed to integrate multidisciplinary facets of basic cancer immunology and immunotherapy to broaden our understanding of ways to harness the immune system to treat cancer.

Click here to learn more about this conference.

Society for Immunotherapy of Cancer

Visit us at SITC 2019

At Gaylord National Hotel & Convention Center, Prince Georges, MD

November 6-10

Talk with one of our scientists at booth 630

Take a look at our latest science at our Posters
(Abstract ID:P75 and P359)

Find out how partnering with us will fast forward your drug discovery and approval pipeline

Stop by our booth to learn if you qualify for a highly discounted pilot program.


Meet immunoSCAPE at ITOC6 in Vienna!

Click here to learn more about this conference.

Keystone Symposia on Molecular and Cellular Biology

Dr Newell and Dr Bonamy to speak at the Keystone Symposia – Cancer Vaccines

Summary of Meeting:
The success of immunotherapy in the treatment of cancer patients has proved the long-standing hypothesis that endogenous adaptive immune responses against the tumor can be harnessed to mediate protection by immune checkpoint blockade. This approach has shown impressive control of disease and improved survival in up to 50% of patients with certain tumors. Genetic and immune analysis of human cancers suggests that one mechanism of resistance to immune checkpoint blockade may be due to lack of tumor-specific T cells. In principle, vaccines have the potential to overcome this defect by either expanding low-level existing tumor-specific T cell responses or priming tumor-specific T cells. Recent advances in next-generation sequencing have improved our understanding of defining cancer antigens. Application of this will require vaccine delivery approaches that can induce potent and broad T cell immunity in an efficient manner for personalized therapy. This Keystone Symposia conference will highlight recent insights in the characterization of immunogenic cancer antigens, the biology and underlying mechanisms of T cell priming, and the development of novel approaches designed to expand T cell responses. Part of the meeting will also be devoted to the development of technologies to monitor T cell responses in response to immune interventions.


Dr. Evan Newell

Dr Newell presentation at the Annual Meeting of the Japanese Society for Immunology

Click here to learn more about this presentation.